This site is intended only for healthcare professionals resident in the United Kingdom
Sign in
Sign In or Register
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

The content of this website has been produced in line with the IBRANCE® Summary of Product Characteristics for Great Britain and Northern Ireland. IBRANCE® (palbociclib) Prescribing Information for Great Britain and Northern Ireland click here.  Adverse event reporting information can be found at the bottom of the page.

Confidence Built on Evidence1

IBRANCE®(palbociclib) is indicated for the treatment of HR+/HER2- locally advanced or mBC in combination with an AI or with fulvestrant in women who have received prior ET. In pre- or peri-menopausal women, the ET should be combined with an LHRH agonist.1 

​​​​​​​IBRANCE® was the first cyclin-dependent kinase 4/6 (CDK4/6) inhibitor approved for HR+/HER2- locally advanced and metastatic breast cancer.1-2

As a 1st line therapy in HR+/HER2- locally advanced and metastatic breast cancer, IBRANCE® + letrozole has demonstrated >2 years median progression free survival vs 14.5 months with letrozole plus placebo in the PALOMA-2 study.2-3 IBRANCE® plus fulvestrant delivers more than double the mPFS compared with fulvestrant monotherapy, 11.2 months with IBRANCE® plus fulvestrant vs. 4.6 months with fulvestrant plus placebo.4-5


Dosing and monitoring requirements for IBRANCE®

More information

Clinical Trials

IBRANCE® PALOMA-2 and PALOMA-3 Clinical Trial Results, including efficacy and safety outcomes

Learn More



Important safety information and safety outcomes from IBRANCE® PALOMA Clinical Trials

See Results

Real World Evidence

Real-world evidence for IBRANCE® (palbociclib) in advanced Breast Cancer


Support for Your Patients

IBRANCE® (palbociclib) Resources to support your patients including a Patient Brochure and Dosing Cards

View Resources

AI : Aromatase Inhibitor,  ET : Endocrine Therapy,  HR+/HER2– : Hormone Receptor Positive / Human Epidermal Growth Factor Receptor 2 Negative,  LHRH : Luteinizing Hormone-Releasing Hormone,  mBC : metastatic Breast Cancer
  1. IBRANCE® Summary of Product Characteristics for Great Britain click here. IBRANCE® Summary of Product Characteristics for Northern Ireland click here.
  2. Finn RS, et al. N Engl J Med. 2016;375(20):1925-1936.
  3. Rugo HS, et al. Breast Cancer Res Treat. 2019;174:719–29.
  4. Cristofanilli M, et al. Lancet Oncol. 2016;17:425–39.
  5. Turner NC et al. N Engl J Med. 2018;379:1926–36.
PP-IBR-GBR-4511. May 2022

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021



OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?